Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Demonstrate whether, in addition to standard of care (SoC), finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to first occurrence of kidney failure, a sustained decrease of eGFR ≥ 40% from baseline over at least 4 weeks or renal death
Critère d'inclusion
- Type II Diabetes Mellitus and Diabetic Kidney Disease